CA
NZ
UK
AU
IND
US
A Form 4 filed on August 14, 2026 with the U.S. Securities and Exchange Commission discloses that Martin Tuchman, a director and 10% owner of Princeton Bancorp, Inc. (NASDAQ:BPRN), purchased 10,534 shares of common stock on August 12, 2026.
A Form 4 filed with the SEC on August 14, 2026, discloses that Jordan M. Denny, Chief Accounting Officer of Valvoline Inc (NYSE:VVV), purchased 1,506 shares of common stock on August 12, 2026.
Tempest Therapeutics, Inc. (NASDAQ: TPST) experienced a significant loss of $32.9 million in its second quarter, reflecting ongoing financial pressures as the company expands its CAR-T pipeline. Despite the challenges, this strategic initiative signals the firm's commitment to advancing its innovative treatments for cancer. …
Tenon Medical, Inc. reported significant improvements in its revenue from the sacroiliac (SI) joint segment during the second quarter of 2026. The company's growth in this area is a positive sign, indicating thatDemandfor its products may be increasing. However, the announcement also brought to …
VolitionRx Ltd (NYSE American: VNRX) disclosed a loss of $14 million, a figure that immediately signals a profound strain on its financial health and forces a reassessment of its capacity to remain an operating entity. The magnitude of this shortfall, coupled with an earnings …
Yarrow Bioscience reported a net loss of $6.5 million for the quarter ended June 30, 2026, as part of its financial results following a merger with VYNE Therapeutics completed on July 27, 2026. This financial performance reflects the costs associated with ongoing clinical development …
Nuwellis, Inc. (NASDAQ: NUWE) generated $2 million in net sales for the second quarter of 2026, marking a 14% increase compared to approximately $1.7 million in the same quarter of the previous year. This growth was primarily driven by an uptick in U.S. sales, …
PetMed Express, Inc. (NASDAQ: PETS) reported net sales of $41 million for the first quarter ending June 30, 2026, which represents a 19.9% decrease from the previous year's $51.2 million. The decline is attributed to a drop in prescription medication sales and lower consumer …
PolyPid Ltd. has made strides in advancing its D-PLEX100 product with the FDA granting Priority Review status, significantly reducing the review timeline. This regulatory acceptance comes ahead of a planned U.S. commercial launch in early 2027, bolstered by a strategic partnership with Azurity Pharmaceuticals. …
RaySearch Laboratories has reported a decline in sales for Q2 2026, attributed largely to regulatory delays in penetrating the U.S. market. This setback raises concerns for investors focused on the company’s growth trajectory, which had anticipated greater contributions from its U.S. operations. The delays …
Please wait processing your request...